Graham Capital Management L.P. Increases Stake in Bausch Health Cos Inc. $BHC

Key Points

• Graham Capital Management L.P. increased its holdings in Bausch Health Cos Inc. by 120.5% in Q1, acquiring 168,122 shares to reach a total of 307,604 shares worth approximately $1.99 million.
• Institutional investors now hold 78.65% of Bausch Health's stock, and recent trading activity includes several new stakes and increases by major financial firms.
• Bausch Health reported a loss of $0.90 EPS for the last quarter, falling short of analysts' expectations, despite revenues surpassing estimates at $2.57 billion.

Graham Capital Management L.P. lifted its position in Bausch Health Cos Inc. (NYSE:BHC - Free Report) by 120.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 307,604 shares of the company's stock after purchasing an additional 168,122 shares during the quarter. Graham Capital Management L.P. owned 0.08% of Bausch Health Cos worth $1,990,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. SBI Securities Co. Ltd. lifted its position in Bausch Health Cos by 244.2% in the 1st quarter. SBI Securities Co. Ltd. now owns 4,230 shares of the company's stock worth $27,000 after buying an additional 3,001 shares during the last quarter. Cary Street Partners Financial LLC bought a new position in Bausch Health Cos during the first quarter valued at approximately $27,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Bausch Health Cos during the first quarter worth approximately $27,000. Wealthquest Corp purchased a new position in shares of Bausch Health Cos during the first quarter worth approximately $58,000. Finally, Hsbc Holdings PLC bought a new stake in shares of Bausch Health Cos in the 1st quarter worth approximately $73,000. 78.65% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised shares of Bausch Health Cos from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Three investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $9.00.

Insiders Place Their Bets

In other Bausch Health Cos news, Director John Paulson acquired 34,721,118 shares of the business's stock in a transaction dated Thursday, August 14th. The shares were purchased at an average cost of $9.00 per share, for a total transaction of $312,490,062.00. Following the transaction, the director owned 70,755,869 shares in the company, valued at $636,802,821. This represents a 96.35% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last three months, insiders purchased 44,316,834 shares of company stock valued at $369,628,560. Company insiders own 19.97% of the company's stock.

Bausch Health Cos Trading Up 1.9%

BHC traded up $0.14 during trading on Friday, hitting $7.35. 1,005,904 shares of the stock traded hands, compared to its average volume of 4,753,792. The firm has a market capitalization of $2.72 billion, a P/E ratio of 28.25 and a beta of 0.48. Bausch Health Cos Inc. has a 12-month low of $4.25 and a 12-month high of $9.85. The company has a debt-to-equity ratio of 141.90, a current ratio of 1.31 and a quick ratio of 0.98. The firm has a 50-day moving average of $6.84 and a 200 day moving average of $6.09.

Bausch Health Cos (NYSE:BHC - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.90 EPS for the quarter, missing the consensus estimate of $0.97 by ($0.07). The firm had revenue of $2.57 billion for the quarter, compared to the consensus estimate of $2.47 billion. Bausch Health Cos had a net margin of 0.99% and a negative return on equity of 852.36%. Bausch Health Cos has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Bausch Health Cos Inc. will post 4.41 EPS for the current year.

Bausch Health Cos Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.